Related content

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

By Lin Nancy  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1057-1065

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

By Lacouture Mario E   Schadendorf Dirk   Chu Chia-Yu   Uttenreuther-Fischer Martina   Stammberger Uz   O'Brien Dennis   Hauschild Axel  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 721-728

Informa Healthcare

Access to resources Recommend Favorite

Diarrhea associated with afatinib: an oral ErbB family blocker

By Yang James Chih-Hsin   Reguart Noemi   Barinoff Jana   Köhler Jens   Uttenreuther-Fischer Martina   Stammberger Uz   O'Brien Dennis   Wolf Jürgen   Cohen Ezra EW  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 729-736

Informa Healthcare

Access to resources Recommend Favorite

ErbB-2 protein in sera and tumors of breast cancer patients

By Breuer Brenda   Smith Steven   Thor Ann   Edgerton Susan   Osborne Michael P.   Minick Richard   Cody   III Hiram S.   Nowak Eugene   Cortese Armand   Simmons Rache M.   Carney Walter P.   Brandt-Rauf Paul W.  

Breast Cancer Research and Treatment, Vol. 49, Iss. 3, 1998-06 ,pp. : 261-270

Springer Publishing Company

Access to resources Recommend Favorite